Dyadic International, Inc. - Common Stock (DYAI)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- P/B of 22.77 — trading above book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -32.8%
- Revenue declining 12% annually
Dyadic International, Inc. - Common Stock (DYAI) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $28 million . Key value metrics: P/B ratio 22.77, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Dyadic International, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, DYAI shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -32.8% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 3.48.
StockPik's composite Value Score for DYAI is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DYAI reports a moderate gross margin of 31.0% (sector average: 39.4%) and a negative operating margin of -207.9%.
DYAI shows revenue declining at 12% year-over-year, with earnings declining at 27%.